ArticleJournal of clinical medicine2020
Maintaining Blood Glucose Levels in Range (70-150 mg/dL) is Difficult in COVID-19 Compared to Non-COVID-19 ICU Patients-A Retrospective Analysis.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Association of the time in targeted blood glucose range of 140 to 180 mg/dL with the mortality of critically ill patients with diabetes: analysis of the MIMIC-IV database.Journal of clinical & translational endocrinology · 2025Article
- Benchmarking Missing Data Imputation Methods for Time Series Using Real-World Test Cases.Proceedings of machine learning research · 2025Article
- The association between enteral nutrition with survival of critical patients with COVID-19.Immunity, inflammation and disease · 2024Article
- A moderately higher time-in-range threshold improves the prognosis of type 2 diabetes patients complicated with COVID-19.Frontiers in endocrinology · 2024Article
- COVID-19 Pneumonia and Increased Insulin Requirement in Known Diabetic Patients: A Prospective Observational Study.Cureus · 2023Article
- Patients with prediabetes are at greater risk of developing diabetes 5 months postacute SARS-CoV-2 infection: a retrospective cohort study.BMJ open diabetes research & care · 2023Article
- Glycemic Control in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection.Reviews in endocrine & metabolic disorders · 2022Review
- Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring.Journal of endocrinological investigation · 2022Article
- The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?Cardiovascular diabetology · 2021Article
- Hyperglycaemia increases mortality risk in non-diabetic patients with COVID-19 even more than in diabetic patients.Endocrinology, diabetes & metabolism · 2021Article
- Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study.BMJ open · 2021Article
- The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes.Endocrinology, diabetes & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta cell dysfunction is suggested in patients with COVID-19 infections. Poor glycemic control in ICU is associated with poor patient outcomes. This is a single center, retrospective analysis of 562 patients in an intensive care unit from 1 March to 30 April 2020. We review the time in range (70-150 mg/dL) spent by critically ill COVID-19 patients and non-COVID-19 patients, along with the daily insulin use. Ninety-three in the COVID-19 cohort and 469 in the non-COVID-19 cohort were compared for percentage of blood glucose TIR (70-150 mg/dL) and average daily insulin use. The COVID-19 cohort spent significantly less TIR (70-150 mg/dL) compared to the non-COVID-19 cohort (44.4% vs. 68.5%). Daily average insulin use in the COVID-19 cohort was higher (8.37 units versus 6.17 units). ICU COVID-19 patients spent less time in range (70-150 mg/dL) and required higher daily insulin dose. A higher requirement for ventilator and days on ventilator was associated with a lower TIR. Mortality was lower for COVID-19 patients who achieved a higher TIR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.